Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527 » 05:33
10/22/20
10/22
05:33
10/22/20
05:33
RHHBY

Roche

$0.00 /

+ (+0.00%)

Atea Pharmaceuticals…

Atea Pharmaceuticals announced that the company has entered into an agreement with Roche for the exclusive rights to research, develop and distribute AT-527 as an oral antiviral treatment for COVID-19 in territories outside of the United States. Under the terms of the agreement, Atea will receive an upfront payment of $350M in cash from Roche with the potential for future milestone payments and royalties.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Yesterday
Periodicals
Boeing in early talks with customers about potential new plane, WSJ reports » 12:40
10/21/20
10/21
12:40
10/21/20
12:40
BA

Boeing

$165.79 /

-1.44 (-0.86%)

, EADSY

Airbus

$0.00 /

+ (+0.00%)

Boeing has held early…

Boeing has held early talks with a few customers to gauge potential interest in a new single-aisle aircraft with improved engines, according to The Wall Street Journal's Benjamin Katz, citing people familiar with the matter. Such a new aircraft model would fall between Boeing's largest 737 MAX and its twin-aisle 787 Dreamliner and "could help it make up lost ground" to rival Airbus (EADSY), the report said. Reference Link

ShowHide Related Items >><<
EADSY Airbus
$0.00 /

+ (+0.00%)

BA Boeing
$165.79 /

-1.44 (-0.86%)

BA Boeing
$165.79 /

-1.44 (-0.86%)

10/13/20 Wells Fargo
Hexcel price target lowered to $42 from $47 at Wells Fargo
10/07/20 Morgan Stanley
Boeing market outlook 'may still be optimistic,' says Morgan Stanley
10/06/20 Credit Suisse
Boeing price target raised to $184 from $154 at Credit Suisse
09/29/20 Morgan Stanley
Morgan Stanley stays Underweight on Boeing despite EASA news
EADSY Airbus
$0.00 /

+ (+0.00%)

10/14/20 Barclays
Airbus price target lowered to EUR 68 from EUR 71 at Barclays
10/13/20 JPMorgan
Airbus downgraded to Underweight from Neutral at JPMorgan
10/01/20 Berenberg
Airbus upgraded to Buy from Hold at Berenberg
09/17/20 Credit Suisse
Airbus price target raised to EUR 106 from EUR 78 at Credit Suisse
EADSY Airbus
$0.00 /

+ (+0.00%)

BA Boeing
$165.79 /

-1.44 (-0.86%)

EADSY Airbus
$0.00 /

+ (+0.00%)

BA Boeing
$165.79 /

-1.44 (-0.86%)

EADSY Airbus
$0.00 /

+ (+0.00%)

BA Boeing
$165.79 /

-1.44 (-0.86%)

BA Boeing
$165.79 /

-1.44 (-0.86%)

Recommendations
Volkswagen price target raised to EUR 190 from EUR 184 at Societe Generale » 11:17
10/21/20
10/21
11:17
10/21/20
11:17
VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Societe Generale analyst Stephen Reitman raised the firm's price target on Volkswagen to EUR 190 from EUR 184 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

10/19/20 Goldman Sachs
Volkswagen price target raised to EUR 179 from EUR 169 at Goldman Sachs
10/15/20 UBS
Volkswagen price target raised to EUR 190 from EUR 180 at UBS
10/07/20 Societe Generale
Volkswagen price target raised to EUR 184 from EUR 148 at Societe Generale
09/08/20 Bernstein
Volkswagen initiated with an Underperform at Bernstein
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

Hot Stocks
PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA » 08:35
10/21/20
10/21
08:35
10/21/20
08:35
PTCT

PTC Therapeutics

$51.40 /

-0.72 (-1.38%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

PTC Therapeutics (PTCT)…

PTC Therapeutics (PTCT) tannounced that Evrysdi was approved in Brazil by the National Health Surveillance Agency for the treatment of spinal muscular atrophy. The approval was obtained within seven months of Roche's (RHHBY) initial submission and marks the second country to approve Evrysdi. Additionally, PTC announced the filing of a New Drug Application for Evrysdi for the treatment of SMA with the Japanese Ministry of Health, Labor and Welfare. The filing in Japan by Chugai Pharmaceutical Co. Ltd., a member of the Roche group, triggers a $7.5M milestone payment to PTC from Roche.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

10/07/20 JPMorgan
PTC Therapeutics upgraded to Overweight with $71 target at JPMorgan
10/07/20 JPMorgan
PTC Therapeutics upgraded to Overweight from Neutral at JPMorgan
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
08/24/20 Raymond James
PTC Therapeutics initiated with an Outperform at Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$51.40 /

-0.72 (-1.38%)

Tuesday
Downgrade
Galapagos downgraded to Sell from Neutral at Goldman Sachs » 19:21
10/20/20
10/20
19:21
10/20/20
19:21
GLPG

Galapagos

$131.98 /

+1.68 (+1.29%)

, ABBV

AbbVie

$84.22 /

-0.09 (-0.11%)

Goldman Sachs analyst…

Goldman Sachs analyst Graig Suvannavejh downgraded Galapagos (GLPG) to Sell from Neutral with a price target of EUR 87, down from EUR 108. The analyst says his updated model includes revised assumptions on the timing of U.S. and the international launches of filgotinib. Suvannavejh adds that he is changing his sales estimates for filgotinib due to a "meaningful delay in the timing of the U.S. launch given receipt of the August 2020 FDA CRL in the initial indication of RA" and sees the program at a considerable competitive disadvantage against AbbVie's (ABBV) Rinvoq.

ShowHide Related Items >><<
GLPG Galapagos
$131.98 /

+1.68 (+1.29%)

ABBV AbbVie
$84.22 /

-0.09 (-0.11%)

GLPG Galapagos
$131.98 /

+1.68 (+1.29%)

10/19/20 Morgan Stanley
Galapagos could move up to 20% on figotinib decision, says Morgan Stanley
10/16/20 UBS
Galapagos price target lowered to EUR 125 from EUR 135 at UBS
10/16/20 RBC Capital
Galapagos price target lowered to $131 from $135 at RBC Capital
10/16/20 Citi
Gilead investors may start questioning Galapagos collaboration, says Citi
ABBV AbbVie
$84.22 /

-0.09 (-0.11%)

10/16/20 JPMorgan
AbbVie price target raised to $120 from $115 at JPMorgan
09/29/20 Berenberg
AbbVie initiated with a Hold at Berenberg
09/28/20 Mizuho
Mizuho 'incrementally more bullish' on AbbVie integration of Allergan
09/02/20 Citi
AbbVie revenue potential offsets subpoena risk, says Citi
GLPG Galapagos
$131.98 /

+1.68 (+1.29%)

ABBV AbbVie
$84.22 /

-0.09 (-0.11%)

GLPG Galapagos
$131.98 /

+1.68 (+1.29%)

ABBV AbbVie
$84.22 /

-0.09 (-0.11%)

ABBV AbbVie
$84.22 /

-0.09 (-0.11%)

Hot Stocks
Prothena, Roche to advance prasinezumab into late-stage clinical development » 16:13
10/20/20
10/20
16:13
10/20/20
16:13
PRTA

Prothena

$11.27 /

+0.13 (+1.17%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Prothena (PRTA), a…

Prothena (PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced that based on positive signals of efficacy consistent with disease modification in the PASADENA study, Roche(RHHBY) and Prothena plan to advance prasinezumab into a Phase 2b study in patients with early Parkinson's disease. The study will be designed to further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA to include patients with early Parkinson's disease on stable levodopa therapy. Prasinezumab is the first anti-alpha synuclein antibody to advance into late-stage development. Prothena will earn a $60 million clinical milestone payment upon first patient dosed in this study. Further details are expected to be announced in the first half of 2021. "We are very encouraged by the results from PASADENA, demonstrating significant slowing of motor progression and improvements on imaging biomarkers consistent with disease modification, as this provides a rich dataset to directly inform and de-risk this next late-stage study," stated Gene Kinney, PhD, president and chief executive officer of Prothena. "Results from the PASADENA study are part of a growing clinical body of evidence suggesting antibodies that optimally target misfolded proteins can result in clinically meaningful benefit. With a growing pipeline of programs based on this scientific approach, Prothena is poised to advance a number of novel therapeutics for devastating diseases."

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

PRTA Prothena
$11.27 /

+0.13 (+1.17%)

PRTA Prothena
$11.27 /

+0.13 (+1.17%)

07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
11/19/19 Evercore ISI
Prothena upgraded to Outperform from In Line at Evercore ISI
RHHBY Roche
$0.00 /

+ (+0.00%)

10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
RHHBY Roche
$0.00 /

+ (+0.00%)

PRTA Prothena
$11.27 /

+0.13 (+1.17%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PRTA Prothena
$11.27 /

+0.13 (+1.17%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Periodicals
Ford plans to launch self-driving business in 2022, CNBC reports » 14:50
10/20/20
10/20
14:50
10/20/20
14:50
F

Ford

$7.79 /

+0.2 (+2.64%)

, VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

Ford Motor (F) plans to…

Ford Motor (F) plans to launch its self-driving commercial business in 2022 with vehicles based on the Ford Escape Hybrid crossover, CNBC's Michael Wayland reports. The vehicles are the automaker's fourth-generation self-driving test vehicles in partnership with Argo AI, a Pittsburgh-based autonomous vehicle start-up. Ford and Volkswagen (VWAGY) split an 80% majority stake in the company earlier this year, the author notes. Ford said the vehicles will begin testing this month alongside its current fleet of roughly 100 autonomous test vehicles that are based off the Fusion Hybrid sedan, which the company is no longer producing. Reference Link

ShowHide Related Items >><<
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

F Ford
$7.79 /

+0.2 (+2.64%)

F Ford
$7.79 /

+0.2 (+2.64%)

10/20/20 Citi
Ford price target raised to $9 from $7.50 at Citi
10/14/20 Goldman Sachs
Ford price target raised to $8 from $7 at Goldman Sachs
10/13/20 Deutsche Bank
Deutsche places 'Buy Catalyst Call' on Ford, ups target to $9
10/12/20
Fly Intel: Top five analyst upgrades
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

10/19/20 Goldman Sachs
Volkswagen price target raised to EUR 179 from EUR 169 at Goldman Sachs
10/15/20 UBS
Volkswagen price target raised to EUR 190 from EUR 180 at UBS
10/07/20 Societe Generale
Volkswagen price target raised to EUR 184 from EUR 148 at Societe Generale
09/08/20 Bernstein
Volkswagen initiated with an Underperform at Bernstein
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

F Ford
$7.79 /

+0.2 (+2.64%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

F Ford
$7.79 /

+0.2 (+2.64%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

F Ford
$7.79 /

+0.2 (+2.64%)

F Ford
$7.79 /

+0.2 (+2.64%)

Periodicals
Volkswagen evaluating interest in potential sale of Ducati brand, Reuters says » 12:29
10/20/20
10/20
12:29
10/20/20
12:29
VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

Volkswagen is holding…

Volkswagen is holding preliminary discussions with potential suitors for its Ducati brand to evaluate interest in the motorcycle maker prior to a November planning round, Reuters' Pamela Barbaglia, Arno Schuetze and Jan Schwartz report, citing three people familiar with the matter. Amid a five-year planning round, the automaker will review the future of its Ducati brand as well as its sports car brands Lamborghini and Bugatti as part of a broader aim for more economies of scale as it moves to mass producing electric vehicles. Reference Link

ShowHide Related Items >><<
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

10/19/20 Goldman Sachs
Volkswagen price target raised to EUR 179 from EUR 169 at Goldman Sachs
10/15/20 UBS
Volkswagen price target raised to EUR 190 from EUR 180 at UBS
10/07/20 Societe Generale
Volkswagen price target raised to EUR 184 from EUR 148 at Societe Generale
09/08/20 Bernstein
Volkswagen initiated with an Underperform at Bernstein
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

Periodicals
Volkswagen gauging possible interest in sale of Ducati brand, Reuters reports  12:21
10/20/20
10/20
12:21
10/20/20
12:21
VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

10/19/20 Goldman Sachs
Volkswagen price target raised to EUR 179 from EUR 169 at Goldman Sachs
10/15/20 UBS
Volkswagen price target raised to EUR 190 from EUR 180 at UBS
10/07/20 Societe Generale
Volkswagen price target raised to EUR 184 from EUR 148 at Societe Generale
09/08/20 Bernstein
Volkswagen initiated with an Underperform at Bernstein
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

Conference/Events
JPMorgan Euro/US pharma/biotech analysts hold analyst/industry conference call » 10:08
10/20/20
10/20
10:08
10/20/20
10:08
BIIB

Biogen

$268.39 /

-0.31 (-0.12%)

, NOVN

Novan

$0.55 /

-0.0128 (-2.29%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, IONS

Ionis Pharmaceuticals

$47.54 /

+0.325 (+0.69%)

European Pharma &…

European Pharma & Biotech Analyst Vosser, US Large Cap biotech Analyst Kasimov and US SMid Biotech Analysts Fye & Joseph discuss the 2020 SMA Physician Survey on an Analyst/Industry conference call to be held on October 20 at 11 am.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

NOVN Novan
$0.55 /

-0.0128 (-2.29%)

IONS Ionis Pharmaceuticals
$47.54 /

+0.325 (+0.69%)

BIIB Biogen
$268.39 /

-0.31 (-0.12%)

BIIB Biogen
$268.39 /

-0.31 (-0.12%)

10/19/20 RBC Capital
Biogen price target lowered to $268 from $281 at RBC Capital
10/05/20 Piper Sandler
MeiraGTx data at least as good as competitors, says Piper Sandler
10/01/20 Morgan Stanley
Biogen panel meeting can be 'perception catalyst' for Lilly, says Morgan Stanley
09/29/20 Morgan Stanley
Aducanumab AdComm could drive Biogen up or down 20%-30%, says Morgan Stanley
NOVN Novan
$0.55 /

-0.0128 (-2.29%)

01/06/20 H.C. Wainwright
Novan price target lowered to $1.50 from $6 at H.C. Wainwright
01/06/20 Piper Sandler
Novan downgraded to Neutral from Overweight at Piper Sandler
01/03/20 H.C. Wainwright
Ligand royalties from Amgen may rise, but Novan hits bump, says H.C Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
IONS Ionis Pharmaceuticals
$47.54 /

+0.325 (+0.69%)

09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/22/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target raised to $59 from $56 at Cantor Fitzgerald
09/14/20 JPMorgan
Ionis Pharmaceuticals resumed with a Neutral at JPMorgan
RHHBY Roche
$0.00 /

+ (+0.00%)

IONS Ionis Pharmaceuticals
$47.54 /

+0.325 (+0.69%)

BIIB Biogen
$268.39 /

-0.31 (-0.12%)

RHHBY Roche
$0.00 /

+ (+0.00%)

BIIB Biogen
$268.39 /

-0.31 (-0.12%)

RHHBY Roche
$0.00 /

+ (+0.00%)

IONS Ionis Pharmaceuticals
$47.54 /

+0.325 (+0.69%)

BIIB Biogen
$268.39 /

-0.31 (-0.12%)

BIIB Biogen
$268.39 /

-0.31 (-0.12%)

BIIB Biogen
$268.39 /

-0.31 (-0.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.